| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2010PLoSO...515251P |
| P356 | DOI | 10.1371/JOURNAL.PONE.0015251 |
| P932 | PMC publication ID | 3001493 |
| P698 | PubMed publication ID | 21179455 |
| P5875 | ResearchGate publication ID | 49703435 |
| P2093 | author name string | James E Galvin | |
| William J Burke | |||
| W Michael Panneton | |||
| V B Kumar | |||
| Qi Gan | |||
| P2860 | cites work | Proteome analysis of human substantia nigra in Parkinson's disease | Q21245637 |
| Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis | Q22242250 | ||
| Astrocytes: biology and pathology | Q27490746 | ||
| Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration | Q28237641 | ||
| Differential behavioral effects of partial bilateral lesions of ventral tegmental area or substantia nigra pars compacta in rats | Q28278798 | ||
| Chronic systemic pesticide exposure reproduces features of Parkinson's disease | Q29614763 | ||
| Genetic mouse models of parkinsonism: strengths and limitations | Q30537732 | ||
| Behavioural effects of parafascicular thalamic lesions in an animal model of parkinsonism | Q46560087 | ||
| Quantitation of 3,4-dihydroxyphenylacetaldehyde and 3, 4-dihydroxyphenylglycolaldehyde, the monoamine oxidase metabolites of dopamine and noradrenaline, in human tissues by microcolumn high-performance liquid chromatography | Q48132783 | ||
| A 6-hydroxydopamine-induced selective parkinsonian rat model: further biochemical and behavioral characterization | Q48151499 | ||
| Effect of bilateral 6-OHDA lesions of the substantia nigra on locomotor activity in the rat. | Q48191276 | ||
| Amphetamine-induced rotational behavior in rats: relationship to hypothalamic and striatal degeneration | Q48252438 | ||
| Unilateral ibotenic acid lesions of the prefrontal cortex reduce rotational behavior in 6-hydroxydopamine-lesioned rats | Q48327331 | ||
| Norepinephrine transmitter metabolite generates free radicals and activates mitochondrial permeability transition: a mechanism for DOPEGAL-induced apoptosis | Q48467216 | ||
| Opposite rotation induced by dopamine agonists in rats with unilateral lesions of the globus pallidus or substantia nigra | Q48468986 | ||
| Levodopa-induced dyskinesia and rotational behavior in hemiparkinsonian rats: independent features or components of the same phenomenon? | Q48580822 | ||
| Norepinephrine transmitter metabolite induces apoptosis in differentiated rat pheochromocytoma cells | Q48682031 | ||
| Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease | Q48830095 | ||
| Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. | Q48876521 | ||
| 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells. | Q52579869 | ||
| Differences in spontaneous and amphetamine-induced rotational behavior, and in sensitization to amphetamine, among Sprague-Dawley derived rats from different sources | Q69673949 | ||
| Effect of dopamine on tyrosine hydroxylase in cultured rat adrenal medulla | Q69916031 | ||
| Circadian variations in the activity of tyrosine hydroxylase, tyrosine aminotransferase, and tryptophan hydroxylase: relationship to catecholamine metabolism | Q72504709 | ||
| Confirmation of a dopamine metabolite in parkinsonian brain tissue by gas chromatography-mass spectrometry | Q72789265 | ||
| Amine oxidase and amine metabolism | Q73076442 | ||
| Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine | Q33344779 | ||
| Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity | Q33617472 | ||
| Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. | Q33941736 | ||
| Glutamate transport and metabolism in dopaminergic neurons of substantia nigra: implications for the pathogenesis of Parkinson's disease | Q34035660 | ||
| Mitochondrial dysfunction--a pathogenetic factor in Parkinson's disease | Q34035698 | ||
| The role of the subthalamic nucleus in the pathophysiology of Parkinson's disease. | Q34628527 | ||
| Caught in the act: alpha-synuclein is the culprit in Parkinson's disease | Q35594818 | ||
| Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases | Q35617408 | ||
| Evaluation of animal models of Parkinson's disease for neuroprotective strategies | Q35920006 | ||
| Design-based stereology in neuroscience | Q36010838 | ||
| Inflammation as a causative factor in the aetiology of Parkinson's disease | Q36052641 | ||
| Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. | Q36265331 | ||
| Expanding insights of mitochondrial dysfunction in Parkinson's disease. | Q36404133 | ||
| Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease | Q36468704 | ||
| Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra | Q36514883 | ||
| Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention | Q36919403 | ||
| Parkinson's disease: genetic versus toxin-induced rodent models | Q37086124 | ||
| The 6-hydroxydopamine model: news from the past | Q37205351 | ||
| A comparison of model-based (2D) and design-based (3D) stereological methods for estimating cell number in the substantia nigra pars compacta (SNpc) of the C57BL/6J mouse | Q37248811 | ||
| Ventral tegmental area leptin receptor neurons specifically project to and regulate cocaine- and amphetamine-regulated transcript neurons of the extended central amygdala | Q40348346 | ||
| Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde | Q40882148 | ||
| Glutamate and Parkinson's disease | Q41056504 | ||
| Experimental models and behavioural tests used in the study of Parkinson's disease | Q41163127 | ||
| The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments | Q41277031 | ||
| Substantia nigra glutamate antagonists produce contralateral turning and basal ganglia Fos expression: interactions with D1 and D2 dopamine receptor agonists | Q41736996 | ||
| Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol | Q41786059 | ||
| Stereological estimates of dopaminergic, GABAergic and glutamatergic neurons in the ventral tegmental area, substantia nigra and retrorubral field in the rat. | Q42063638 | ||
| Asymmetrically lesioned mesencephalon in healthy rodents: call for caution | Q42467210 | ||
| Blockade of subthalamic glutamatergic activity corrects changes in neuronal metabolism and motor behavior in rats with nigrostriatal lesions. | Q42508137 | ||
| Total number of neurons in the neostriatal, pallidal, subthalamic, and substantia nigral nuclei of the rat basal ganglia: a stereological study using the cavalieri and optical disector methods | Q42524102 | ||
| Decreased susceptibility to oxidative stress underlies the resistance of specific dopaminergic cell populations to paraquat-induced degeneration | Q42685088 | ||
| Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior | Q43412942 | ||
| Dopaminergic lateralisation in the forebrain: relations to behavioural asymmetries and anxiety in male Wistar rats | Q43565506 | ||
| Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria | Q43570259 | ||
| 3,4-Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson's disease pathogenesis | Q43725921 | ||
| Astroglial and microglial reaction after a partial nigrostriatal degeneration induced by the striatal injection of different doses of 6-hydroxydopamine | Q43792780 | ||
| Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease | Q44013447 | ||
| Relationships between various behavioural abnormalities and nigrostriatal dopamine depletion in the unilateral 6-OHDA-lesioned rat. | Q44365334 | ||
| 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis | Q44616102 | ||
| ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson's disease and in the ventral tegmental area in schizophrenia | Q44695580 | ||
| Circadian patterns of neurotransmitter related gene expression in motor regions of the rat brain | Q44796722 | ||
| Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease | Q46452329 | ||
| Postural changes after lesions of the substantia nigra pars reticulata in hemiparkinsonian monkeys. | Q46465349 | ||
| P275 | copyright license | Creative Commons CC0 License | Q6938433 |
| P6216 | copyright status | copyrighted, dedicated to the public domain by copyright holder | Q88088423 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| neurotoxicity | Q3338704 | ||
| toxic encephalopathy | Q7830379 | ||
| P304 | page(s) | e15251 | |
| P577 | publication date | 2010-12-13 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis | |
| P478 | volume | 5 |
| Q55361950 | 3,4-Dihydroxyphenylacetaldehyde-Induced Protein Modifications and Their Mitigation by N-Acetylcysteine. |
| Q34560077 | A vesicular sequestration to oxidative deamination shift in myocardial sympathetic nerves in Parkinson's disease |
| Q37701053 | Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice |
| Q24632904 | Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease |
| Q82938754 | Animal models of Parkinson's disease |
| Q34065897 | Benomyl, aldehyde dehydrogenase, DOPAL, and the catecholaldehyde hypothesis for the pathogenesis of Parkinson's disease |
| Q77792019 | Bioanalytical and mass spectrometric methods for aldehyde profiling in biological fluids |
| Q34358267 | Bone marrow-derived mesenchymal stem cells increase dopamine synthesis in the injured striatum |
| Q37957562 | Cardiovascular dysautonomia in Parkinson disease: from pathophysiology to pathogenesis |
| Q26826093 | Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders |
| Q55048859 | Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease. |
| Q28387863 | Cellular localization of dieldrin and structure-activity relationship of dieldrin analogues in dopaminergic cells |
| Q35875871 | Classic and new animal models of Parkinson's disease |
| Q36559682 | Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells |
| Q58794925 | Compensatory Expression of Nur77 and Nurr1 Regulates NF-B-Dependent Inflammatory Signaling in Astrocytes |
| Q36992085 | Concepts of scientific integrative medicine applied to the physiology and pathophysiology of catecholamine systems |
| Q52543567 | Covalent modification of biological targets with natural products through Paal-Knorr pyrrole formation. |
| Q36494097 | DOPAL is transmissible to and oligomerizes alpha-synuclein in human glial cells. |
| Q33896138 | Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease |
| Q38112217 | Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson's disease |
| Q36505602 | Direct intranigral injection of dopaminochrome causes degeneration of dopamine neurons |
| Q33771253 | Divalent metal ions enhance DOPAL-induced oligomerization of alpha-synuclein. |
| Q39607510 | Dopamine-derived biological reactive intermediates and protein modifications: Implications for Parkinson's disease. |
| Q34463831 | Dysautonomia in Parkinson disease |
| Q91933521 | Effect of ALDH2 on Sleep Disturbances in Patients with Parkinson's Disease |
| Q41655727 | Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies |
| Q93129655 | Impaired dopamine metabolism in Parkinson's disease pathogenesis |
| Q39294770 | Linking Stress, Catecholamine Autotoxicity, and Allostatic Load with Neurodegenerative Diseases: A Focused Review in Memory of Richard Kvetnansky |
| Q48176779 | N-Acetylcysteine Prevents the Increase in Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in PC12 Cells |
| Q34029794 | Natural toxins implicated in the development of Parkinson's disease |
| Q37669523 | Neurochemical and motor changes in mice with combined mutations linked to Parkinson's disease |
| Q34181738 | Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease |
| Q35557892 | Neuroprotective effects of aldehyde dehydrogenase 2 activation in rotenone-induced cellular and animal models of parkinsonism |
| Q29541727 | Neurotoxicity of the Parkinson Disease-Associated Pesticide Ziram Is Synuclein-Dependent in Zebrafish Embryos |
| Q38021940 | Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson's disease pathogenesis |
| Q35181537 | Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease |
| Q36987273 | Stress, allostatic load, catecholamines, and other neurotransmitters in neurodegenerative diseases |
| Q37590347 | Stress, allostatic load, catecholamines, and other neurotransmitters in neurodegenerative diseases |
| Q37614069 | Sympathetic neuroimaging |
| Q34395219 | Targeting aldehyde dehydrogenase 2: new therapeutic opportunities |
| Q28830423 | Toxic Dopamine Metabolite DOPAL Forms an Unexpected Dicatechol Pyrrole Adduct with Lysines of α-Synuclein |
| Q28075913 | Toxin-Induced Experimental Models of Learning and Memory Impairment |
| Q39044780 | Use of monoamine oxidase inhibitors in chronic neurodegeneration |
| Q36445937 | Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease |
| Q64870070 | α-Synuclein stimulation of monoamine oxidase-B and legumain protease mediates the pathology of Parkinson's disease |
Search more.